Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.

A cytotoxic T lymphocyte (CTL) clone generated in vitro from the peripheral blood of a healthy HLA-A2-positive individual against a synthetic p53 protein-derived wild-type peptide (L9V) was shown to kill squamous carcinoma cell lines derived from two head and neck carcinomas, which expressed mutant p53 genes, in a L9V/HLA-A2 specific and restricted fashion. Thus, the normal tolerance against endogenously processed p53 protein-derived self-epitopes can be broken by peptide-specific in vitro priming. p53 protein-derived wild-type peptides might thus represent tumor associated target molecules for immunotherapeutical approaches.

[1]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Eberlein,et al.  Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. , 1995, Journal of immunology.

[3]  S. Sak,et al.  Overexpression of p53 in Laryngeal Carcinoma: Clinicopathological Implications , 1995, Ear, nose, & throat journal.

[4]  M. Claesson,et al.  T Cell‐Mediated Cytotoxicity Against p53‐Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors , 1995, Scandinavian journal of immunology.

[5]  Wei Chen,et al.  Immunity to Oncogenic Proteins , 1995, Immunological reviews.

[6]  R. Brasseur,et al.  BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.

[7]  P. Devilee,et al.  Somatic genetic changes in human breast cancer. , 1994, Biochimica et biophysica acta.

[8]  S. H. van der Burg,et al.  p53, a potential target for tumor-directed T cells. , 1994, Immunology letters.

[9]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Old,et al.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[12]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[13]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.

[14]  Fearon Er.  Molecular genetic studies of the adenoma-carcinoma sequence. , 1994 .

[15]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[16]  J Alexander,et al.  Antigen analogs/MHC complexes as specific T cell receptor antagonists. , 1994, Annual review of immunology.

[17]  W. Kast,et al.  Potential immunogenicity of oncogene and tumor suppressor gene products. , 1993, Current opinion in immunology.

[18]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[19]  P. Barber,et al.  P53 overexpression and Epstein‐Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas , 1993, The Journal of pathology.

[20]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[21]  M. Jung,et al.  Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. , 1992, Cancer research.

[22]  M. Jäättelä,et al.  Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. , 1992, The EMBO journal.

[23]  M. Boyce-Jacino,et al.  HLA class II "typing": direct sequencing of DRB, DQB, and DQA genes. , 1992, Human immunology.

[24]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[25]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.

[26]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[27]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.